A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort.
作者信息
Ruiz-Antorán Belén, Sancho-López Aránzazu, Torres Ferrán, Fernández-Cruz Ana
机构信息
Clinical Pharmacology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Medical Statistics Core Facility, August Pi i Sunyer Biomedical Research Institute, Hospital Clinic, Barcelona, Spain.
出版信息
Infect Dis Ther. 2021 Sep;10(3):1811-1813. doi: 10.1007/s40121-021-00444-4. Epub 2021 Apr 29.
Abstract
摘要
相似文献
1
A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort.对《致编辑的信：关于托珠单抗与类固醇联合使用以改善重症新型冠状病毒肺炎感染患者死亡率：一项西班牙多中心队列研究》的回应
Infect Dis Ther. 2021 Sep;10(3):1811-1813. doi: 10.1007/s40121-021-00444-4. Epub 2021 Apr 29.
2
Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.致编辑的信：关于托珠单抗与类固醇联合使用以改善重症新型冠状病毒肺炎感染患者死亡率的研究：一项西班牙多中心队列研究
Infect Dis Ther. 2021 Sep;10(3):1807-1809. doi: 10.1007/s40121-021-00443-5. Epub 2021 Apr 29.
3
Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.托珠单抗与类固醇联合使用以改善重症 COVID-19 感染患者的死亡率：一项西班牙多中心队列研究。
Infect Dis Ther. 2021 Mar;10(1):347-362. doi: 10.1007/s40121-020-00373-8. Epub 2020 Dec 6.
4
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
5
Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.皮质类固醇和托珠单抗可降低重症 COVID-19 肺炎患者的院内死亡率：一项西班牙医院的回顾性研究
Infect Dis (Lond). 2021 Apr;53(4):291-302. doi: 10.1080/23744235.2021.1884286. Epub 2021 Feb 23.
6
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.COVID-19 病毒感染管理的 COVIRL002 试验-托珠单抗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
7
Long-term effect of tocilizumab on mortality, readmissions, persistent symptoms and lung function in SARS-CoV-2 patients 1 year after hospital discharge: A matched cohort study.托珠单抗对出院后 1 年 SARS-CoV-2 患者死亡率、再入院率、持续症状和肺功能的长期影响：一项匹配队列研究。
Respir Med Res. 2023 Nov;84:101064. doi: 10.1016/j.resmer.2023.101064. Epub 2023 Nov 4.
8
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.COVID-19 重症患者早期使用托珠单抗治疗与死亡率的关联。
JAMA Intern Med. 2021 Jan 1;181(1):41-51. doi: 10.1001/jamainternmed.2020.6252.
9
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
10
Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study.影响重症COVID-19疾病稳定性及托珠单抗治疗反应的因素：一项回顾性队列研究
Antibiotics (Basel). 2022 Aug 9;11(8):1078. doi: 10.3390/antibiotics11081078.
引用本文的文献
1
Prevalence of NSAID use among people with COVID-19 and the association with COVID-19-related outcomes: Systematic review and meta-analysis.COVID-19 患者中使用非甾体抗炎药（NSAIDs）的流行情况及其与 COVID-19 相关结局的关联：系统评价和荟萃分析。
Br J Clin Pharmacol. 2022 Dec;88(12):5113-5127. doi: 10.1111/bcp.15512. Epub 2022 Sep 20.
本文引用的文献
1
Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.致编辑的信：关于托珠单抗与类固醇联合使用以改善重症新型冠状病毒肺炎感染患者死亡率的研究：一项西班牙多中心队列研究
Infect Dis Ther. 2021 Sep;10(3):1807-1809. doi: 10.1007/s40121-021-00443-5. Epub 2021 Apr 29.
Zotero 插件